Clinical TrialOct 26, 2026, 06:06 AM
ArriVent BioPharma: ARR-217 Shows 44.8% ORR in GI Cancer Phase 1 Trial
AI Summary
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate, ARR-217 (MRG007), in patients with gastrointestinal cancers. The data, presented at the European Society for Medical Oncology Congress 2026, showed a 44.8% objective response rate (ORR) at the 6mg/kg dose in late-line colorectal cancer patients, with a generally well-tolerated safety profile. The company is advancing ARR-217 into a Phase 1b dose optimization study, with further data anticipated in 2027. ArriVent will host a webinar to discuss these results.
Key Highlights
- ArriVent announces initial Phase 1 data for ARR-217 (MRG007) in gastrointestinal cancers at ESMO Congress 2026.
- 44.8% Objective Response Rate (ORR) observed at 6mg/kg Q3W dose in pre-treated Colorectal Cancer (CRC) patients.
- 93.1% Disease Control Rate (DCR) observed at 6mg/kg Q3W dose in CRC patients.
- ARR-217 was generally well-tolerated with most treatment-related adverse events being Grade 1/2.
- 30.1% of patients experienced Grade 3 or higher treatment-related adverse events across all doses.
- ArriVent to host a webinar on October 26, 2026, to discuss the ARR-217 data.
- Phase 1b dose optimization study is ongoing at 5 and 6 mg/kg Q3W doses, with data expected in 2027.
Price Impact
More from AVBP